Skip to content

    Jeena Sikho Q1 FY27 earnings call

    JSLL
    Consumer Services·10 Aug 2026
    Management Summary

    Jeena Sikho reported strong Q1 FY27 results with 29% YoY revenue growth and robust margins, driven by its integrated healthspan philosophy and growth in both product and service segments. The company is strategically reducing government business, expanding into ultra-luxury wellness, and preparing for Ayushman Yojana. Investments in technology and operational efficiency are underway to support ambitious long-term targets of ₹3,000 crores turnover and ₹1,000 crores PAT.

    Highlights

    5
    • Revenue from operations grew 29% YoY to ₹224 crores in Q1 FY27.

    • EBITDA grew 17% YoY to ₹92 crores, maintaining a healthy 41% margin.

    • PAT reached ₹65 crores, with a 28% margin.

    • Ayurveda healthcare product business showed strong growth of 47% YoY, reaching ₹118 crores.

    • Private Panchakarma revenue increased over 30% YoY to ₹100 crores, supported by 33% YoY IPD patient growth and 31% YoY daycare volume increase.

    Concerns

    3
    • Quarter-on-quarter revenue appeared flat, though management attributed this to strategic reduction in government business.

    • A significant portion of the 'other income' (₹7 crores out of ₹14 crores) was one-time, from warrant valuation and capital gains.

    • Increased advertisement expenses (₹4 crores) and software implementation costs (₹2 crores) were booked as one-off expenses in Q1, impacting current quarter profitability.

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue from Operations₹224 Cr+29.0%YoY
    2. 02EBITDA₹92 Cr+17%YoY
    3. 03EBITDA Margin41%
    4. 04PAT₹65 Cr
    5. 05PAT Margin28%

    Segment breakdown

    Ayurveda Healthcare Service Business
    ₹100 Cr Panchakarma Private Revenue₹5 Cr Panchakarma Government Revenue33% IPD Patients YoY Growth31% Daycare Volume YoY Growth21% OPD Volume YoY Growth143% COD & Consulting Patients YoY Growth65% VOPD Consultation YoY Growth2,400 number Operational Beds59% Occupancy
    Ayurveda Healthcare Product Business
    ₹118 Cr Revenue2,64,000 number E-commerce Volume18,500 number COD Volume
    List

    Guidance & targets

    15
    CategoryTargetPriority
    Revenue
    Revenue Growth
    30%
    High
    Revenue
    Turnover
    INR3000 crores
    High
    Revenue
    Manali Center ADR (Year 1)
    32,000 to 35,000
    Medium
    Revenue
    Manali Center ADR (Year 2)
    35,000 to 37,000
    Medium
    Profitability
    PAT
    INR1,000 crores
    High
    Profitability
    Net Profit Margin
    27% to 30%
    High
    Profitability
    EBITDA Margin
    40% plus
    High
    Profitability
    Manali Center EBITDA (Year 1)
    35% to 40% plus
    Medium
    Profitability
    Manali Center Gross Margin (Year 2)
    60%, 62%
    Medium
    Profitability
    New Luxury Wellness Centers Profit
    INR3 crores to INR5 crores
    Medium
    Capacity
    Operational Beds
    7,000 to 10,000
    High
    Capacity
    Operational Beds
    3,000 to 3,500
    High
    Capacity
    Manali Center Occupancy (Year 1)
    50%
    Medium
    Capacity
    Manali Center Occupancy (Year 2)
    60%
    Medium
    Occupancy
    Occupancy Rate
    75%,80%
    High

    What to watch in Q2 FY27

    5

    Impact of New Advertisement Campaigns

    Next quarter
    Current₹4 crores spent in Q1 FY27
    TargetIncreased patient footfall and sales

    Why it matters

    Ad spend is a significant expense, its effectiveness will drive future growth and is expected to yield results in the next quarter.

    my advertisement expense of INR4 crores has increased. But its outcome will come in the next quarter.

    Risks & concerns

    3
    RiskSeverity

    Strategic reduction in government business

    Reduced government business from INR 15 crores to INR 5 crores due to long payment cycles and bad debt risk, impacting current quarter revenue but improving cash flow.Management acknowledged

    medium

    Regulatory delays for new facilities

    Delays in obtaining NOCs and approvals (e.g., Panvel hospital's 49 beds to 250 beds expansion) can slow down capacity expansion and revenue realization.Management acknowledged

    medium

    Impact of pricing strategy for affordability

    Offering discounts for BPL/poor patients to increase occupancy and doctor practice might impact average ticket size/revenue per patient, though seen as a long-term strategic investment.Management acknowledged

    low

    Q&A highlights

    8

    “No, sir. Please don't judge us quarter-on-quarter. If you look at our patient count and volume, overall quarter-on-quarter growth is 10%. We modify our business approach based on future requirements. If I have to scale turnover to INR3000 crores, I need to adjust strategies -- making patients return repeatedly, coming for recurring care, and learning to stay healthy. Our per-day day care volume increased from 16,000 to 19,000, which will further rise going forward. Let me explain once you finish your complete question.”

    Analyst questioned flat QoQ revenue, management clarified strategic reduction in government business and focus on private, cash-rich model, emphasizing overall patient volume growth.

    asked by Karanveer Singh

    2 min read7 chapters

    Detailed Narrative

    01

    Q1 FY27 Financial Performance Overview

    Jeena Sikho reported a strong Q1 FY27 with revenue from operations reaching INR 224 crores, marking a 29% year-on-year growth. EBITDA stood at INR 92 crores, growing 17% YoY and maintaining a healthy 41% margin. The company achieved a PAT of INR 65 crores, reflecting a 28% margin, demonstrating the strength and scalability of its operating model.

    02

    Integrated Business Model and Healthspan Philosophy

    The company's core philosophy centers on 'prevention is the only cure' and extending 'healthspan'. Its integrated business model ensures that services and products are not separate, but mutually reinforcing. Patients engage through health awareness, consultations, OPD, products, and IPD, with post-treatment follow-ups and Ayurvedic medicines fostering long-term relationships and recurring engagement.

    03

    Strategic Shift in Service Business and Volume Growth

    Jeena Sikho strategically reduced its government business from INR 15 crores to INR 5 crores in Q1 FY27 to mitigate long payment cycles and bad debt risks, focusing on a cash-rich private model. Despite this, private Panchakarma revenue grew over 30% YoY to INR 100 crores. This growth was supported by a 33% YoY increase in IPD patients, a 31% YoY increase in daycare volume, and a 10% QoQ growth in overall patient count to 534,000.

    04

    Robust Product Business Performance

    The Ayurveda healthcare product business continued its strong trajectory, growing 47% YoY to INR 118 crores in Q1 FY27. This performance is driven by an expanding product portfolio, a growing customer base, and increasing acceptance of quality-focused Ayurvedic offerings. E-commerce volume for products increased from 228,000 to 264,000, and COD volume grew from 14,000 to 18,500.

    05

    Expansion into Ultra-Luxury Wellness and Ayushman Yojana Strategy

    The company is launching an ultra-luxury wellness center in Manali, featuring 108 rooms and 22 villas, operating on a lease model with minimal operating costs. It targets 50% occupancy, INR 32,000-35,000 ADR, and 35-40%+ EBITDA margin in year one. Additionally, Jeena Sikho is proactively engaging with the Ayushman Yojana scheme, planning to admit patients at discounted cash rates within 10 days to build doctor practice and occupancy, anticipating future scheme benefits.

    06

    Technological and Operational Enhancements

    Jeena Sikho is investing significantly in technology and corporate governance. It has implemented Salesforce and Oracle for real-time data and improved reporting efficiency, now providing results within 7-8 days. The company is also developing an app for recurring Panchakarma, enhancing clinical protocols, conducting clinical trials, and training doctors, aiming for a 'digital CEO' approach and a research-based ecosystem.

    07

    Long-Term Vision and Ambitious Targets

    Management reiterated its ambitious long-term vision to build a comprehensive health operating system. Key financial targets include achieving INR 3,000 crores in turnover and INR 1,000 crores in PAT within 3-5 years, maintaining 30% YoY revenue growth, 27-30% net profit margin, and 40%+ EBITDA margin. The company also aims to expand its operational bed capacity to 7,000-10,000 beds with 75-80% occupancy in the same timeframe.

    This is an AI-generated summary of a publicly available earnings call transcript.